ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Thrombophilia and Thrombotic Complications in Armenia

H. Khachatryan1, L. Sahakyan2, N. Sargsyan1,3, L. Petrosyan1, L. Hambardzumyan2,4, I. Melnichenko3,4, S. Petrosyan5, G. Tamamyan3,4, S. Danielyan2

1Armenian Hemophilia and Thrombophilia Center, Hematology Center after Prof. R.H.Yeolyan, Yerevan, Armenia, 2Hematology Center after Prof. R.H.Yeolyan, Yerevan, Armenia, 3Pediatric Cancer and Blood Disorders Center of Armenia, Hematology Center after Prof. R.H.Yeolyan, Yerevan, Armenia, 4Yerevan State Medical University, Pediatric Oncology and Hematology, Yerevan, Armenia, 5Sourb Grigor Lusavorich Medical Center, Neurology, Yerevan, Armenia

Abstract Number: PB2241

Meeting: ISTH 2020 Congress

Theme: Venous Thromboembolism and Cardioembolism » Thrombophilia

Background: The incidence of hereditary thrombophilia varies considerably in different countries and populations. Data on the epidemiology of thrombophilia and thrombotic events in Armenia is very limited or lacking.

Aims: The aim of this study was to analyze the incidence of thrombophilia in Armenian population for the period of 2009-2019 and to evaluate the frequency of thrombotic complications and recurrent thrombosis among patients with thrombophilia.

Methods: The data for this study have been derived from the ambulance cards, hospitalization journals, and medical records of the Registry of the Armenian Hemophilia and Thrombophilia Center, Hematology Center after Prof. R.H.Yeolyan. Demographic data were obtained from the Statistical Committee of the Republic of Armenia.

Results: For the whole group of patients the median age was 28.7 years, range [16-60] During the study period 189 primary patients with FV homozygote, 71 with FII homozygote thrombophilia were registered. 97 (37%) patients had both FV and FII homozygous mutations. The average annual incidence for patients with FV homozygote mutation was 0.6±0.10 and FII homozygous mutation 0.23±0.06 per 100 000 population. 47 (18%) patients had recurrent thrombosis. The average annual detectability from the general population was 0.01%. Thrombotic complications of different locations were observed in 98 (38%) patients. Regarding heterozygous mutations, there were 840 (0.29±0.01) FV carriers and 258 (0.89±0.01 per 100 000 population) FII carriers detected.

Conclusions: Our Center is the only hemostasis and thrombosis institution in our country and to the best of our knowledge this is the first report to describe the epidemiological situation of hereditary thrombophilia and recurrent thrombosis in Armenian population.

To cite this abstract in AMA style:

Khachatryan H, Sahakyan L, Sargsyan N, Petrosyan L, Hambardzumyan L, Melnichenko I, Petrosyan S, Tamamyan G, Danielyan S. Thrombophilia and Thrombotic Complications in Armenia [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/thrombophilia-and-thrombotic-complications-in-armenia/. Accessed October 1, 2023.

« Back to ISTH 2020 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/thrombophilia-and-thrombotic-complications-in-armenia/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley